Natera (NTRA) UBS Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
UBS Global Healthcare Conference summary
11 Nov, 2026Leadership transition
Solomon's elevation to CEO follows long involvement in Prospera and Signatera development, clinical strategy, R&D, and commercial rollout.
Transition was described as operationally continuous: Solomon already chairs or participates deeply in key decisions, while Steve remains available under a transition agreement.
A tenured leadership and sales team, collaborative decision-making, and established commercial processes are expected to preserve execution and customer focus.
Revenue framework and Signatera
2029 framework targets $6B revenue, roughly double the level just above $3B; management characterized it as achievable through multiple volume and ASP paths, without relying on early-detection revenue.
Signatera ASP is currently $1,290; management cited ~$1,450 as an achievable 2029 planning level and retained a longer-term goal of $2,000, versus contracted rates in the mid-$3,000s.
Reimbursement expansion is a key ASP lever: additional MolDX submissions for tumor types collectively representing up to one-third of volumes, plus progress in biomarker states and Medicare Advantage compliance.
MRD remains early, with estimated single-digit penetration of a $15B-$30B annual revenue market; Signatera is expected to exceed $1B revenue this year.
Volume growth and investment
The latest quarter recorded 318,000 units and 33,000 sequential growth; year-on-year volume growth was 113,000 units, a record by more than 10,000.
Management said year-on-year volume growth is now more useful than sequential changes for assessing acceleration; trailing four-quarter averages also remain relevant.
Signatera commercial staffing aspiration is 300-400 people, with continued iteration and growth expected; incremental investment emphasis remains on R&D, especially clinical trials.
Most OpEx growth this year and next is directed to R&D; ~$100M of this year's $900M-$950M-plus R&D budget is for colorectal cancer and early detection, with no current top-line contribution.
Latest events from Natera
- Signatera growth, new assay evidence and early cancer detection underpin a $6B-plus 2029 target.NTRA
Jefferies Global Healthcare Conference - A $6B 2029 target and expanding cancer-testing opportunity frame the outlook.NTRA
8th Annual Wolfe Research Healthcare Conference - Revenue grew 34% as volumes climbed, lifting FY2026 guidance and supporting a $6B 2029 target.NTRA
Q3 2026 - Record growth, expanding global reach, and innovation drive strong financial and operational results.NTRA
2026 Global Healthcare Conference - Record MRD growth, expanding biopharma ties, and innovation set the stage for sustained expansion.NTRA
Morgan Stanley 24th Annual Global Healthcare Conference - Record Q2 growth, product innovation, and global expansion drive strong outlook.NTRA
Canaccord Genuity's 46th Annual Growth Conference - Revenue up 38% to $753M, record test volumes, improved margins, and raised guidance.NTRA
Q2 2026 - Record growth, innovation, and AI-driven strategies are accelerating adoption and market expansion.NTRA
Morgan Stanley 23rd Annual Global Healthcare Conference - Record growth, innovation, and clinical momentum set the stage for major milestones in 2025.NTRA
43rd Annual J.P. Morgan Healthcare Conference 2025